focus -WSS

focus

author：fashion 2025-08-26 23:48:45 - browse：5169

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Mom launches Girl Scout troop for LGBTQ youth in Texas

explore

WSS

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Community addresses injustice for Long Island mothers

Australia's humpback populations rebound raising hopes of marine scientists

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Community addresses injustice for Long Island mothers

Australia's humpback populations rebound raising hopes of marine scientists

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Psychedelics group wrestles with new pharma identity

When is a doctor not a doctor? Try when patients address women doctors

In age of alternative facts, a scholarly course on calling out crap

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Malaria cases in Florida and Texas: Here’s what you need to know

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Drug repurposing or repositioning? The language matters

A public health expert passes on football's full body collisions for youths

Sports medicine is finally prioritizing gender equality

Meta looks to target Twitter with a rival app called Threads

hotspot

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Eli Lilly’s Mounjaro succeeds in second weight

4th of July breaks record for highest global temperature ever measured

Australia's humpback populations rebound raising hopes of marine scientists

These geoengineering technologies could help combat the climate crisis, scientists say

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

explore

explore

Wikipedia

entertainment